Utilizing Reinforcement Learning for de novo Drug Design
Svensson, Hampus Gummesson, Tyrchan, Christian, Engkvist, Ola, Chehreghani, Morteza Haghir
–arXiv.org Artificial Intelligence
Deep learning-based approaches for generating novel drug molecules with specific properties have gained a lot of interest in the last years. Recent studies have demonstrated promising performance for string-based generation of novel molecules utilizing reinforcement learning. In this paper, we develop a unified framework for using reinforcement learning for de novo drug design, wherein we systematically study various on- and off-policy reinforcement learning algorithms and replay buffers to learn an RNN-based policy to generate novel molecules predicted to be active against the dopamine receptor DRD2. Our findings suggest that it is advantageous to use at least both top-scoring and low-scoring molecules for updating the policy when structural diversity is essential. Using all generated molecules at an iteration seems to enhance performance stability for on-policy algorithms. In addition, when replaying high, intermediate, and low-scoring molecules, off-policy algorithms display the potential of improving the structural diversity and number of active molecules generated, but possibly at the cost of a longer exploration phase. Our work provides an open-source framework enabling researchers to investigate various reinforcement learning methods for de novo drug design.
arXiv.org Artificial Intelligence
Mar-30-2023
- Country:
- North America > United States
- New York > New York County
- New York City (0.04)
- California > San Diego County
- San Diego (0.04)
- New York > New York County
- Europe > Sweden
- Vaestra Goetaland > Gothenburg (0.04)
- North America > United States
- Genre:
- Research Report > New Finding (1.00)
- Industry:
- Technology: